Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Critical reviews in oncogenesis

Volumn 17, Issue 1, 2012, Pages 1-16

  Rexer, Brent N ^a   Arteaga, Carlos L ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84861516765     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v17.i1.20     Document Type: Review

References (0)